Immunodeficiency

Immunology·MeSH: Immunologic Deficiency Syndromes

Prevalence

5.0 / 100K

54 drugs in development·17 companies·3 clinical trials

Drug Pipeline by Phase

Approved(11)

Drug	Company
ASCENIV	ADMA BIOLOGICS, INC. (ADMA)
BIVIGAM	ADMA BIOLOGICS, INC. (ADMA)
cutaquig	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
cuvitru	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
darunavir	Mylan II B.V. (MYL)
etravirine	Amneal Pharmaceuticals, Inc. (AMRX)
fosamprenavir	Mylan II B.V. (MYL)
gammagard liquid	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
hizentra	KORU Medical Systems Inc. Common Stock (DE) (KRMD)
nevirapine	Mylan II B.V. (MYL)
xembify	KORU Medical Systems Inc. Common Stock (DE) (KRMD)

Phase 3(14)

Drug	Company
Doravirine	Merck & Co., Inc. (MRK)
Emtricitabine/tenofovir disoproxil	Merck & Co., Inc. (MRK)
hyqvia	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
hyqvia	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
immune globulin	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
ISL	Merck & Co., Inc. (MRK)
MK-8527	Merck & Co., Inc. (MRK)
tak-771	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-771	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-881	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-881	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-881	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
ULO	Merck & Co., Inc. (MRK)
Unrelated donor bone marrow transplant	Filana Therapeutics Inc. (FLNA)

Phase 2(12)

Drug	Company
2 NRTIs	Merck & Co., Inc. (MRK)
Base-edited hematopoietic stem and progenitor cells	Structure Therapeutics Inc. (GPCR)
BIC/FTC/TAF	Merck & Co., Inc. (MRK)
Busulfan	Filana Therapeutics Inc. (FLNA)
Combined LAI Treatment	COLLEGIUM PHARMACEUTICAL, INC (COLL)
DOR/3TC/TDF	Merck & Co., Inc. (MRK)
Haploidentical donor bone marrow transplant	Filana Therapeutics Inc. (FLNA)
Hematopoietic stem cell transplant	Structure Therapeutics Inc. (GPCR)
ISL/ULO	Merck & Co., Inc. (MRK)
Plerixafor	Structure Therapeutics Inc. (GPCR)
Unrelated donor bone marrow transplant	Structure Therapeutics Inc. (GPCR)
Vorinostat	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(11)

Drug	Company
Busulfan	Structure Therapeutics Inc. (GPCR)
hb-500	HOOKIPA Pharma Inc. (HOOK)
hb-502	HOOKIPA Pharma Inc. (HOOK)
MGD014	UNITED THERAPEUTICS Corp (UTHR)
MGD014	MACROGENICS INC (MGNX)
MGD020	MACROGENICS INC (MGNX)
MGD020	UNITED THERAPEUTICS Corp (UTHR)
Palifermin	Merus N.V. (MRUS)
Palifermin	Structure Therapeutics Inc. (GPCR)
Peripheral Blood Stem Cell Infusion	Structure Therapeutics Inc. (GPCR)
Plerixafor	Merus N.V. (MRUS)

Phase 1/Phase 2(1)

Drug	Company
IMC-M113V	Immunocore Holdings plc (IMCR)

Phase 2/Phase 3(1)

Drug	Company
PRO 140	CytoDyn Inc. (CYDY)

Phase 4(4)

Drug	Company
bictegravir/emtricitabine/tenofovir alafenamide	GH Research PLC (GHRS)
Filgrastim	Structure Therapeutics Inc. (GPCR)
immune globulin	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Pegfilgrastim	Structure Therapeutics Inc. (GPCR)

BioSniper tracks 54 drugs in development for Immunodeficiency across 17 companies.

There are 3 clinical trials targeting Immunodeficiency tracked by BioSniper.

The estimated prevalence of Immunodeficiency is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.